Figure 1 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors

2026 Open access

Read full text Summarise with VIRAT
Authors: David William Thomas, Jeong Suk Kim, Fabrice Barlési, Uwe M. Martens, Maciej Jerzy Krzakowski, Rafał Dziadziuszko, Jae Ho Jeong, Gennaro Daniele, Timothy Richard Wilson, Felice Wu, Brian Simmons, Sid Patel
+3 more Maria Sbirnac, Monika Kaul, Shirish M. Gadgeel
DOI: 10.1158/1078-0432.31744587
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

TAPISTRY cohort D flow diagram. Overall, 150 patients were enrolled (ITT). The safety-evaluable population consisted of 148 patients; 129 patients with ≥13 mut/Mb were included in the efficacy-evaluable population, and 112 patients with ≥16 mut/Mb were included in the analysis of the primary endpoint. ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intent to treat.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

Publication details

Publication date
16 March 2026
Language
EN